- $LLY (+0,32 %) Total sales: USD 13.53 billion (45% increase on the previous year) just below the forecast of USD 13.55 billion
- Adjusted earnings more than doubled, rising 114% to USD 5.32 per share. (Earnings significantly exceeded expectations of USD 5.06 per share)
- Mounjaro (type 2 diabetes): USD 3.53 billion (expected: USD 3.63 billion )
- Zepbound (obesity): USD 1.91 billion (expected: USD 1.99 billion )
- Trulicity (type 2 diabetes): USD 1.25 billion (26% decrease) (expected: USD 1.34 billion)
Forecast for 2025
- Total sales: USD 58 to 61 billion (expected: USD 58.77 billion)
- Adjusted earnings per share: USD 22.50 to 24.00 (earnings of USD 22.76 per share expected)